NO336898B1 - Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse - Google Patents
Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse Download PDFInfo
- Publication number
- NO336898B1 NO336898B1 NO20061528A NO20061528A NO336898B1 NO 336898 B1 NO336898 B1 NO 336898B1 NO 20061528 A NO20061528 A NO 20061528A NO 20061528 A NO20061528 A NO 20061528A NO 336898 B1 NO336898 B1 NO 336898B1
- Authority
- NO
- Norway
- Prior art keywords
- oxo
- amino
- isoindol
- dihydro
- crystalline
- Prior art date
Links
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 title claims abstract 49
- 239000008194 pharmaceutical composition Substances 0.000 title claims 14
- 239000000203 mixture Substances 0.000 title claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- 239000007787 solid Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 238000001757 thermogravimetry curve Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- NIUJOYSLCREXIZ-UHFFFAOYSA-N 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;dihydrate Chemical compound O.O.C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O NIUJOYSLCREXIZ-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
- B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
- B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
- B65D51/2857—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
- B65D51/2864—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mechanical Engineering (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
Det beskrives polymorfe former av 3-(4-amino-l.okso-1,3 dihydro-isoindol-2-yl)piperidin-2,6-dion. Det beskrives videre polymorfe former, fremstillingsmåter for fremstilling av de polymorfe former og anvendelse av disse.
Claims (49)
1.
Krystallinsk 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion hemihydrat.
2.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 1,karakterisert vedat det har et røntgenpulver diffraksjonsmønster som omfatter topper på 16, 22, og 27 grader 20.
3.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 2,karakterisert vedat røntgenpulver diffraksjonstoppene er rundt 16, 22 og 27 grader 20.
4.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 2,karakterisert vedat røntgenpulver diffraksjonsmønsteret videre omfatter en topp på 18 grader 20.
5.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 4,karakterisert vedat røntgenpulver diffraksjonstoppene videre er på rundt 18 grader 20.
6.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1-5,karakterisert vedat det har et differensielt skanningkalorimetrisk-termogram omfattende endotermer med maksima på 146°C og 268°C.
7.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1-6,karakterisert vedat det mister mellom 3,1% og 3,952% flyktige forbindelser i forhold til vekt når det varmes opp til 175°C.
8.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1-7,karakterisert veddet har mellom rundt 0,46 mol og 0,60 mol vann per mol av 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
9.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion dihydrat.
10.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 9,karakterisert vedad det har et røntgenpulver diffraksjonsmønster omfattende topper på 20, 24,5 og 29 grader 26.
11.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 10,karakterisert vedat røntgenpulver diffraksjonstoppene er rundt 20, 24,5 og 29 grader 20.
12.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 9 til 11,karakterisertv e d at det har et differensielt skanningkalorimetrisk-termogram som omfatter endotermer med maksima på 99°C og 269°C.
13.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion i følge hvilket som helst av kravene 9-11,karakterisert vedat det mister mellom 11,3% og 12,0% flyktige forbindelser i forhold til vekt når det varmes opp til 175°C.
14.
Krystallinsk 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dionkarakterisert vedat det har et røntgenpulver diffraksjonsmønster omfattende topper på rundt 8, 14,5 og 16 grader 20.
15.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 14,karakterisert vedat røntgenpulver diffraksjonstoppene er 8, 14,5 og 16 grader 20.
16.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 14 eller 15,karakterisertv e d at røntgenpulver diffraksjonsmønstret videre omfatter topper på 17,5, 20,5, 24 og 26 grader 20.
17.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge krav 16,karakterisert vedet røntgenpulver diffraksjonstoppene videre er rundt 17,5, 20,5, 24 og 26 grader 20.
18.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 14-17,karakterisert vedat det har et differensielt skanningkalorimetrisk-termogram som omfatter en endoterm med et maksimum på 270°C.
19.
Krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 14 til 18,karakterisertved at det er usolvatisert.
20.
Fast form av 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion,karakterisert vedat det omfatter det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1-19, der det krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er til stede i mer enn 80 vekt % av den faste formen.
21.
Fast form ifølge krav 20,karakterisert vedat den krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er til stede i mer enn 90 vekt % av den faste formen.
22.
Fast form ifølge krav 20,karakterisert vedat den krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er til stede i mer enn 95 vekt % av den faste formen.
23.
Fast form i følge krav 20,karakterisert vedat den krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er til stede i mer enn 97 vekt % av den faste formen.
24.
Blanding av det krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 8 og det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 9-13.
25.
Sammensetningkarakterisert vedat den omfatter amorf 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion og det krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1-19.
26.
Sammensetning ifølge krav 25,karakterisert vedat den omfatter mer enn 50 vekt% krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
27.
Sammensetning ifølge krav 25,karakterisert vedat den omfatter mer enn 75 vekt% krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
28.
Sammensetning ifølge krav 25,karakterisert vedat den omfatter mer enn 90 vekt% krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
29.
Sammensetning ifølge krav 25,karakterisert vedat den omfatter mer enn 95 vekt% krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
30.
Farmasøytisk sammensetningkarakterisert vedat den omfatter krystallinsk 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 eller den faste formen ifølge et hvilket som helst av kravene 20 til 23 eller sammensetningen ifølge et hvilket som helst av kravene 25 til 29 og en farmasøytisk akseptabel eksipient, diluent eller bærer.
31.
Farmasøytisk sammensetning ifølge krav 30,karakterisertv e d at den er i enkel enhetsdoseform.
32.
Farmasøytisk sammensetning ifølge krav 30,karakterisertv e d at den er en tablett.
33.
Farmasøytisk sammensetning ifølge krav 30,karakterisertv e d at den er en kapsel.
34.
Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 31-33,karakterisert vedat den omfatter 5 mg av det krystallinske 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
35.
Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 31-33,karakterisert vedat den omfatter 10 mg av det krystallinske 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
36.
Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 31 til 33,karakterisert vedat den omfatter 25 mg av det krystallinske 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
37.
Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 31 til 33,karakterisert vedat den omfatter 50 mg av det krystallinske 3-(4-amino-1 -okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion.
38.
Anvendelse av en terapeutisk eller profylaktisk effektiv mengde av det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av en farmasøytisk sammensetning for behandling av en cancer.
39.
Anvendelse ifølge krav 38, der canceren er en fast tumor eller en blodbåren tumor.
40.
Anvendelse av en terapeutisk eller profylaktisk effektiv mengde av det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av en farmasøytisk sammensetning for behandling eller forebygging av uønsket angjogenese, en inflammatorisk sykdom, en autoimmun sykdom eller en immun sykdom.
41.
Anvendelse av en terapeutisk eller profylaktisk effektiv mengde av det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av en farmasøytisk sammensetning for behandling eller forebygging av et myelodysplastisk syndrom.
42.
Anvendelse av en terapeutisk eller profylaktisk effektiv mengde av det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av en farmasøytisk sammensetning for behandling eller forebygging av en myeloproliferativ sykdom.
43.
Anvendelse av en terapeutisk eller profylaktisk mengde av det krystallinske 3-(4-amino-l-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av en farmasøytisk sammensetning for behandling eller forebygging av en blodbåren tumor.
44.
Anvendelse ifølge et hvilket som helst av kravene 38 til 43, der det krystallinske 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion blir fremstilt for å administreres oralt, parenteralt, nasalt, topisk eller sublingualt.
45.
Anvendelse ifølge krav 44, der det krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion blir fremstilt for å administreres oralt.
46.
Anvendelse ifølge krav 45, der det krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er i tablettform.
47.
Anvendelse ifølge krav 45, der det krystallinske 3-(4-amino-l-okso-l,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion er i kapselform.
48.
Anvendelse ifølge et hvilket som helst av kravene 45-47, der den terapeutiske eller profylaktiske mengde er fra 0,10 mg til 150 mg per dag.
49.
Anvendelse ifølge et hvilket som helst av kravene 45-47, der den terapeutiske eller profylaktiske mengde er fra 5 mg til 25 mg per dag.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49972303P | 2003-09-04 | 2003-09-04 | |
PCT/US2004/028736 WO2005023192A2 (en) | 2003-09-04 | 2004-09-03 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20061528L NO20061528L (no) | 2006-06-02 |
NO336898B1 true NO336898B1 (no) | 2015-11-23 |
Family
ID=34272860
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061528A NO336898B1 (no) | 2003-09-04 | 2006-04-04 | Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse |
NO20150253A NO337446B1 (no) | 2003-09-04 | 2015-02-23 | Polymorfe former av 3-(4-amino-1-okso-1,3 dihydro-isonidol-2-yl)-piperidin-1,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse. |
NO20160131A NO341039B1 (no) | 2003-09-04 | 2016-01-28 | Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion |
NO20161012A NO341035B1 (no) | 2003-09-04 | 2016-06-15 | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20150253A NO337446B1 (no) | 2003-09-04 | 2015-02-23 | Polymorfe former av 3-(4-amino-1-okso-1,3 dihydro-isonidol-2-yl)-piperidin-1,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse. |
NO20160131A NO341039B1 (no) | 2003-09-04 | 2016-01-28 | Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion |
NO20161012A NO341035B1 (no) | 2003-09-04 | 2016-06-15 | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion |
Country Status (37)
Country | Link |
---|---|
US (20) | US7465800B2 (no) |
EP (7) | EP1667682B1 (no) |
JP (6) | JP4733037B2 (no) |
KR (3) | KR100979869B1 (no) |
CN (7) | CN104059052A (no) |
AP (1) | AP2324A (no) |
AR (2) | AR047994A1 (no) |
AT (1) | ATE531369T1 (no) |
AU (2) | AU2004270211B2 (no) |
BR (1) | BRPI0414084A (no) |
CA (9) | CA2687924C (no) |
CR (2) | CR8291A (no) |
CY (1) | CY1112017T1 (no) |
DK (5) | DK3045175T3 (no) |
EA (1) | EA009922B1 (no) |
EC (1) | ECSP066467A (no) |
ES (5) | ES2718925T3 (no) |
GE (1) | GEP20104958B (no) |
HK (6) | HK1092388A1 (no) |
HR (1) | HRP20110836T1 (no) |
HU (3) | HUE041265T2 (no) |
IL (5) | IL174067A (no) |
IS (1) | IS8340A (no) |
MA (1) | MA28084A1 (no) |
ME (3) | ME01530B (no) |
MX (6) | MX346260B (no) |
NO (4) | NO336898B1 (no) |
NZ (1) | NZ546054A (no) |
OA (1) | OA13250A (no) |
PE (1) | PE20060284A1 (no) |
PL (5) | PL3045176T3 (no) |
PT (5) | PT2426118E (no) |
RS (3) | RS20120339A1 (no) |
SI (2) | SI1667682T1 (no) |
UA (1) | UA83504C2 (no) |
WO (1) | WO2005023192A2 (no) |
ZA (1) | ZA200601858B (no) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0510110A (pt) * | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
ME01513B (me) | 2005-06-30 | 2014-04-20 | Celgene Corp | Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona |
KR20080026198A (ko) * | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원 |
EP1919365A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
US7928280B2 (en) * | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
US8105634B2 (en) * | 2006-08-15 | 2012-01-31 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
WO2008060377A2 (en) | 2006-10-04 | 2008-05-22 | Anthrogenesis Corporation | Placental or umbilical cord tissue compositions |
KR20160093739A (ko) | 2006-10-06 | 2016-08-08 | 안트로제네시스 코포레이션 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
NZ584458A (en) | 2007-09-28 | 2012-09-28 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
EP2262768A4 (en) * | 2008-03-11 | 2011-03-23 | Reddys Lab Ltd Dr | PREPARATION OF LENALIDOMIDE |
US20110060010A1 (en) * | 2008-03-13 | 2011-03-10 | Tianjin Hemay Bio-Tech Co., Ltd | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
AU2009321374A1 (en) * | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | A crystalline form of lenalidomide and a process for its preparation |
DE102008057335A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Amorphes Lenalidomid |
EP2355802A1 (de) * | 2008-11-14 | 2011-08-17 | Ratiopharm GmbH | Intermediate und orale darreichungsformen enthaltend lenalidomid |
DE102008057285A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung |
DE102008057284A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Tabletten enthaltend Lenalidomid und Adhäsionsverstärker |
WO2010056384A1 (en) * | 2008-11-17 | 2010-05-20 | Dr. Reddy's Laboratories Ltd. | Lenalidomide solvates and processes |
WO2010065939A1 (en) | 2008-12-05 | 2010-06-10 | Indiana University Research & Technology Corporation | Combination therapy to enhace nk cell mediated cytotoxicty |
US8946265B2 (en) | 2009-03-02 | 2015-02-03 | Generics [Uk] Limited | Process for the preparation of lenalidomide |
WO2010129636A2 (en) * | 2009-05-08 | 2010-11-11 | Dr. Reddy's Laboratories Ltd. | Lenalidomide polymorph |
JP5752677B2 (ja) | 2009-05-19 | 2015-07-22 | セルジーン コーポレイション | 4−アミノ−2−(2,6−ジオキソピペリジン−3−イル)イソインドリン−1,3−ジオンの製剤 |
CN101665484B (zh) * | 2009-07-20 | 2012-11-21 | 上海皓元生物医药科技有限公司 | 一种制备来那度胺的方法 |
EA201270261A1 (ru) | 2009-08-12 | 2012-07-30 | Синтон Б. В. | Соли леналидомида |
EP2477973B1 (en) | 2009-09-16 | 2014-08-27 | Ranbaxy Laboratories Limited | Process for the preparation of a crystalline form of lenalidomide |
TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011050962A1 (en) | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN102127054B (zh) * | 2009-11-02 | 2013-04-03 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102060842B (zh) * | 2009-11-02 | 2013-05-08 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN101696205B (zh) * | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011061611A1 (en) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
WO2011069608A1 (en) | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
CN101817813B (zh) * | 2010-01-15 | 2013-04-10 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物 |
ES2713482T3 (es) | 2010-02-11 | 2019-05-22 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
EP2582836B1 (en) | 2010-06-18 | 2018-03-07 | Taiho Pharmaceutical Co., Ltd. | Prpk-tprkb modulators and uses thereof |
US9918197B2 (en) | 2010-10-04 | 2018-03-13 | Lazo Inc. | Interactive advertisement environment |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
CN102070606A (zh) * | 2011-02-17 | 2011-05-25 | 江苏先声药物研究有限公司 | 一种雷利度胺a晶型新的制备方法 |
CN102643266B (zh) * | 2011-02-17 | 2015-02-18 | 江苏先声药物研究有限公司 | 一种雷利度胺b晶型的制备方法 |
AR085650A1 (es) | 2011-03-11 | 2013-10-16 | Celgene Corp | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y usos |
EP2688649B1 (en) * | 2011-03-23 | 2019-04-10 | Hetero Research Foundation | A polymorph of lenalidomide |
CA2867134C (en) | 2011-03-28 | 2019-05-07 | Sheila Dewitt | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
US9643950B2 (en) * | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
CN104072476B (zh) * | 2013-03-27 | 2018-08-21 | 江苏豪森药业集团有限公司 | 泊马度胺晶型及其制备方法和用途 |
WO2014170909A2 (en) * | 2013-04-01 | 2014-10-23 | Hetero Research Foundation | Process for pomalidomide |
US10260885B2 (en) * | 2013-09-03 | 2019-04-16 | Fugro Chance, Inc. | Interactive remote guidance system for seaborne vessels |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
EP2875817B1 (en) * | 2013-11-26 | 2020-03-18 | Synhton B.V. | Pharmaceutical formulation comprising amorphous lenalidomide |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
CN104016966A (zh) * | 2014-01-30 | 2014-09-03 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
WO2015113314A1 (zh) * | 2014-01-30 | 2015-08-06 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
AR100153A1 (es) * | 2014-04-22 | 2016-09-14 | Otsuka Pharma Co Ltd | Medicamento |
CN105085473B (zh) * | 2014-04-24 | 2019-06-18 | 江苏豪森药业集团有限公司 | 来那度胺晶型及其制备方法和医药用途 |
US20170107193A1 (en) * | 2014-04-26 | 2017-04-20 | Shilpa Medicare Limited | Crystalline lenalidomide process |
US20150348512A1 (en) * | 2014-06-01 | 2015-12-03 | Apple Inc. | Method and apparatus for representing a device's traversal along a route |
US10392364B2 (en) | 2014-08-11 | 2019-08-27 | Avra Laboratories Pvt. Ltd. | Process for synthesis of lenalidomide |
HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
US9794331B1 (en) * | 2014-09-29 | 2017-10-17 | Amazon Technologies, Inc. | Block allocation based on server utilization |
EP3233059A1 (en) | 2014-12-19 | 2017-10-25 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
WO2016097025A1 (en) | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
CN104447689B (zh) * | 2014-12-22 | 2016-07-20 | 上海迈柏医药科技有限公司 | 来那度胺的晶型及其制备方法 |
CN104610210B (zh) * | 2015-02-05 | 2017-06-16 | 天津大学 | 一种脱氢醋酸钠无水物制备方法 |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
EP3744318A1 (en) | 2015-08-27 | 2020-12-02 | Grindeks, A Joint Stock Company | Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications |
AU2016378482A1 (en) | 2015-12-22 | 2018-07-12 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
RU2616976C1 (ru) * | 2016-04-07 | 2017-04-19 | Олег Ростиславович Михайлов | Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе |
WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
TWI664172B (zh) * | 2016-08-25 | 2019-07-01 | 大陸商浙江海正藥業股份有限公司 | 來那度胺的晶型及其製備方法和用途 |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CA3049435A1 (en) | 2017-01-09 | 2018-07-12 | Scott Grindrod | Selective histone deacetylase inhibitors for the treatment of human disease |
CN108658935A (zh) * | 2017-03-27 | 2018-10-16 | 天津大学 | 来那度胺新晶型、其制备方法及其医药用途 |
US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
CN112062751A (zh) * | 2017-08-04 | 2020-12-11 | 正大天晴药业集团股份有限公司 | 一种来那度胺的新结晶及其药物组合物 |
JP2020533383A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
WO2019067792A1 (en) | 2017-09-28 | 2019-04-04 | Celularity, Inc. | TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY |
CN111278432A (zh) | 2017-10-26 | 2020-06-12 | 赛比亚斯药业股份公司 | 来那度胺速释制剂 |
EP3505158A1 (en) | 2017-12-27 | 2019-07-03 | KRKA, d.d., Novo mesto | Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt |
CN108191826A (zh) * | 2018-01-08 | 2018-06-22 | 浙江省医学科学院 | 一种来那度胺晶体及其制备方法 |
CN112004537A (zh) | 2018-01-09 | 2020-11-27 | 穿梭药业公司 | 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂 |
WO2019138424A1 (en) | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
CN108840908A (zh) * | 2018-07-10 | 2018-11-20 | 刘凤娟 | 特拉匹韦的一种新晶型及其制备方法 |
CN111217792B (zh) * | 2018-11-23 | 2021-09-28 | 欣凯医药化工中间体(上海)有限公司 | 一种来那度胺b晶型的制备方法 |
MX2023008091A (es) | 2021-01-08 | 2023-07-14 | Starton Therapeutics Inc | Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral. |
WO2023126531A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Lenalidomide oral solution |
WO2023126530A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Oral solution comprising lenalidomide |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
EP0789584B1 (de) * | 1994-11-04 | 2001-09-19 | Polymun Scientific Immunbiologische Forschung GmbH | Applikation von sod in liposomen |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
DE19601303A1 (de) | 1996-01-16 | 1997-07-17 | Boehringer Ingelheim Kg | Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln |
JPH1053576A (ja) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | 塩酸ドネペジルの多形結晶およびその製造法 |
AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
ES2187805T7 (es) * | 1996-07-24 | 2018-08-17 | Celgene Corporation | 2-(2,6-Dioxopiperidin-3-il)-ftalimidas y 1-oxoisoindolinas y método para reducir los niveles de TNF-alfa |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
EP1920773B1 (en) | 1996-11-05 | 2011-01-05 | The Children's Medical Center Corporation | Thalidomide and dexamethasone for the treatment of tumors |
WO1998035021A1 (en) | 1997-02-05 | 1998-08-13 | University Of Hertfordshire | Preparation of spheroids and their use in medicin or diagnosis |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
AU745884B2 (en) | 1998-03-16 | 2002-04-11 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US20030013739A1 (en) | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
DK1163219T3 (da) | 1999-03-18 | 2006-02-27 | Celgene Corp | Substituerede 1-oxo- og 1,3-dioxoisoindoler og deres anvendelse i farmaceutiske præparater til reduktion af inflammatoriske cytokinniveauer |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
CA2396079A1 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
CA2319872C (en) | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
CZ20023330A3 (cs) | 2000-03-17 | 2003-02-12 | Cell Therapeutics, Inc. | Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy |
KR20030003708A (ko) | 2000-03-31 | 2003-01-10 | 셀진 코포레이션 | 시클로옥시게나제-2 활성의 저해 |
NZ522767A (en) | 2000-05-15 | 2004-07-30 | Celgene Corp | Thalidomide and a topoisomerase inhibitor for the treatment of cancer |
BR0114196A (pt) * | 2000-09-26 | 2003-07-22 | Reddy S Res Foundation | Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas. |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US20020128228A1 (en) | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
PT1423115E (pt) | 2001-08-06 | 2009-07-21 | Childrens Medical Center | Actividade antiangiogénica de análogos da talidomida substituídos com nitrogénio |
US6472563B1 (en) | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
NZ536050A (en) | 2002-04-12 | 2007-11-30 | Celgene Corp | Methods of identifying modulators of angiogenesis using stem cells with the proviso the stems cells are not totipotent |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
NZ563281A (en) | 2002-05-17 | 2009-05-31 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CL2004001004A1 (es) | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
KR20070057907A (ko) | 2004-09-03 | 2007-06-07 | 셀진 코포레이션 | 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법 |
US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
US20090092343A1 (en) * | 2007-10-05 | 2009-04-09 | Mary Thomson | Locking Bag with Locking Handle |
EP2262768A4 (en) * | 2008-03-11 | 2011-03-23 | Reddys Lab Ltd Dr | PREPARATION OF LENALIDOMIDE |
CN101531653B (zh) | 2008-03-13 | 2014-07-09 | 峡江和美药业有限公司 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
WO2010019435A2 (en) | 2008-08-14 | 2010-02-18 | Teva Pharmaceutical Industries Ltd. | Solid states of atorvastatin potassium |
AU2009321374A1 (en) | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | A crystalline form of lenalidomide and a process for its preparation |
EP2355802A1 (de) * | 2008-11-14 | 2011-08-17 | Ratiopharm GmbH | Intermediate und orale darreichungsformen enthaltend lenalidomid |
WO2010056384A1 (en) | 2008-11-17 | 2010-05-20 | Dr. Reddy's Laboratories Ltd. | Lenalidomide solvates and processes |
US8946265B2 (en) | 2009-03-02 | 2015-02-03 | Generics [Uk] Limited | Process for the preparation of lenalidomide |
WO2010129636A2 (en) | 2009-05-08 | 2010-11-11 | Dr. Reddy's Laboratories Ltd. | Lenalidomide polymorph |
CN101580501B (zh) | 2009-06-01 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体 |
EA201270261A1 (ru) | 2009-08-12 | 2012-07-30 | Синтон Б. В. | Соли леналидомида |
EP2493872A1 (en) | 2009-09-03 | 2012-09-05 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
EP2477973B1 (en) | 2009-09-16 | 2014-08-27 | Ranbaxy Laboratories Limited | Process for the preparation of a crystalline form of lenalidomide |
TWI475014B (zh) | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011050962A1 (en) | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011061611A1 (en) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
WO2011069608A1 (en) | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
CN101817813B (zh) | 2010-01-15 | 2013-04-10 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物 |
WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
CN101791288B (zh) | 2010-04-07 | 2011-12-28 | 南京卡文迪许生物工程技术有限公司 | 一种稳定的来那度胺口服固体制剂 |
CN102453021A (zh) * | 2010-10-22 | 2012-05-16 | 重庆医药工业研究院有限责任公司 | 来那度胺的新晶型及其制备方法 |
-
2004
- 2004-03-09 UA UAA200603659A patent/UA83504C2/uk unknown
- 2004-09-03 CA CA 2687924 patent/CA2687924C/en not_active Expired - Lifetime
- 2004-09-03 CN CN201410197941.9A patent/CN104059052A/zh active Pending
- 2004-09-03 DK DK15199526.3T patent/DK3045175T3/en active
- 2004-09-03 ES ES15199521T patent/ES2718925T3/es not_active Expired - Lifetime
- 2004-09-03 CN CN2010101862271A patent/CN101863878B/zh not_active Expired - Fee Related
- 2004-09-03 ES ES15199526T patent/ES2718926T3/es not_active Expired - Lifetime
- 2004-09-03 MX MX2012014272A patent/MX346260B/es unknown
- 2004-09-03 MX MXPA06001994A patent/MXPA06001994A/es active IP Right Grant
- 2004-09-03 PL PL15199540T patent/PL3045176T3/pl unknown
- 2004-09-03 ME MEP-2008-776A patent/ME01530B/me unknown
- 2004-09-03 RS RS20120339A patent/RS20120339A1/en unknown
- 2004-09-03 CA CA 2741412 patent/CA2741412C/en not_active Expired - Lifetime
- 2004-09-03 CN CN200480030852XA patent/CN1871003B/zh not_active Expired - Fee Related
- 2004-09-03 ES ES04783095T patent/ES2376879T3/es not_active Expired - Lifetime
- 2004-09-03 CN CN201210126780.5A patent/CN102675281B/zh not_active Expired - Fee Related
- 2004-09-03 CA CA 2688709 patent/CA2688709C/en not_active Expired - Lifetime
- 2004-09-03 EP EP04783095A patent/EP1667682B1/en not_active Revoked
- 2004-09-03 OA OA1200600078A patent/OA13250A/en unknown
- 2004-09-03 PT PT111857678T patent/PT2426118E/pt unknown
- 2004-09-03 EA EA200600535A patent/EA009922B1/ru not_active IP Right Cessation
- 2004-09-03 PT PT15199526T patent/PT3045175T/pt unknown
- 2004-09-03 PT PT15199521T patent/PT3042659T/pt unknown
- 2004-09-03 HU HUE15199526A patent/HUE041265T2/hu unknown
- 2004-09-03 CN CN2010101862479A patent/CN101838261B/zh not_active Expired - Fee Related
- 2004-09-03 MX MX2012014442A patent/MX346372B/es unknown
- 2004-09-03 ES ES11185767T patent/ES2402808T3/es not_active Expired - Lifetime
- 2004-09-03 KR KR20067004521A patent/KR100979869B1/ko active IP Right Review Request
- 2004-09-03 DK DK04783095.5T patent/DK1667682T3/da active
- 2004-09-03 PT PT15199540T patent/PT3045176T/pt unknown
- 2004-09-03 PL PL15199521T patent/PL3042659T3/pl unknown
- 2004-09-03 US US10/934,863 patent/US7465800B2/en active Active
- 2004-09-03 DK DK11185767T patent/DK2426118T3/da active
- 2004-09-03 GE GEAP20049329A patent/GEP20104958B/en unknown
- 2004-09-03 RS RS20120340A patent/RS53104B/en unknown
- 2004-09-03 JP JP2006525471A patent/JP4733037B2/ja not_active Expired - Lifetime
- 2004-09-03 ES ES15199540T patent/ES2718927T3/es not_active Expired - Lifetime
- 2004-09-03 CA CA 2688694 patent/CA2688694C/en not_active Expired - Lifetime
- 2004-09-03 EP EP20110185757 patent/EP2425836A1/en not_active Withdrawn
- 2004-09-03 ME MEP-2012-98A patent/ME01572B/me unknown
- 2004-09-03 EP EP15199521.4A patent/EP3042659B8/en not_active Revoked
- 2004-09-03 DK DK15199521.4T patent/DK3042659T3/en active
- 2004-09-03 KR KR1020087012598A patent/KR20080063862A/ko not_active Application Discontinuation
- 2004-09-03 ZA ZA200601858A patent/ZA200601858B/en unknown
- 2004-09-03 CA CA2537092A patent/CA2537092C/en not_active Expired - Lifetime
- 2004-09-03 PL PL15199526T patent/PL3045175T3/pl unknown
- 2004-09-03 HU HUE15199540A patent/HUE041282T2/hu unknown
- 2004-09-03 EP EP20110185767 patent/EP2426118B1/en not_active Expired - Lifetime
- 2004-09-03 HU HUE15199521A patent/HUE042071T2/hu unknown
- 2004-09-03 PT PT04783095T patent/PT1667682E/pt unknown
- 2004-09-03 SI SI200431775T patent/SI1667682T1/sl unknown
- 2004-09-03 CA CA 2688695 patent/CA2688695C/en not_active Expired - Lifetime
- 2004-09-03 CA CA2741575A patent/CA2741575C/en not_active Expired - Lifetime
- 2004-09-03 RS YUP20060158 patent/RS20060158A/sr unknown
- 2004-09-03 CN CN2012100174979A patent/CN102584788A/zh active Pending
- 2004-09-03 AP AP2006003558A patent/AP2324A/xx active
- 2004-09-03 PL PL04783095T patent/PL1667682T3/pl unknown
- 2004-09-03 MX MX2013002127A patent/MX342025B/es unknown
- 2004-09-03 CA CA 2687927 patent/CA2687927C/en not_active Expired - Lifetime
- 2004-09-03 CN CN2011100226894A patent/CN102060843B/zh not_active Expired - Fee Related
- 2004-09-03 EP EP15199526.3A patent/EP3045175B8/en not_active Revoked
- 2004-09-03 WO PCT/US2004/028736 patent/WO2005023192A2/en active Application Filing
- 2004-09-03 NZ NZ546054A patent/NZ546054A/en not_active IP Right Cessation
- 2004-09-03 CA CA 2688708 patent/CA2688708C/en not_active Expired - Lifetime
- 2004-09-03 SI SI200432022T patent/SI2426118T1/sl unknown
- 2004-09-03 EP EP18184669.2A patent/EP3459544A1/en not_active Withdrawn
- 2004-09-03 BR BRPI0414084-2A patent/BRPI0414084A/pt not_active Application Discontinuation
- 2004-09-03 ME MEP-2012-97A patent/ME01571B/me unknown
- 2004-09-03 DK DK15199540.4T patent/DK3045176T3/en active
- 2004-09-03 PL PL11185767T patent/PL2426118T3/pl unknown
- 2004-09-03 EP EP15199540.4A patent/EP3045176B8/en not_active Revoked
- 2004-09-03 AT AT04783095T patent/ATE531369T1/de active
- 2004-09-03 MX MX2012014277A patent/MX346261B/es unknown
- 2004-09-03 AU AU2004270211A patent/AU2004270211B2/en active Active
- 2004-09-03 KR KR1020097015932A patent/KR101005991B1/ko active IP Right Review Request
-
2005
- 2005-03-04 AR ARP050100841A patent/AR047994A1/es not_active Application Discontinuation
- 2005-03-04 PE PE2005000248A patent/PE20060284A1/es not_active Application Discontinuation
-
2006
- 2006-02-21 MX MX2013006320A patent/MX342071B/es unknown
- 2006-03-02 IL IL174067A patent/IL174067A/en not_active IP Right Cessation
- 2006-03-07 IS IS8340A patent/IS8340A/is unknown
- 2006-03-15 CR CR8291A patent/CR8291A/es not_active Application Discontinuation
- 2006-03-30 EC ECSP066467 patent/ECSP066467A/es unknown
- 2006-04-03 MA MA28911A patent/MA28084A1/fr unknown
- 2006-04-04 NO NO20061528A patent/NO336898B1/no unknown
- 2006-12-22 HK HK06114094.0A patent/HK1092388A1/xx not_active IP Right Cessation
-
2008
- 2008-07-23 US US12/220,336 patent/US7977357B2/en active Active
- 2008-12-15 US US12/335,395 patent/US7855217B2/en active Active
- 2008-12-15 US US12/335,350 patent/US8143286B2/en active Active
- 2008-12-15 US US12/335,262 patent/US8058443B2/en active Active
-
2009
- 2009-01-14 US US12/353,383 patent/US9365538B2/en active Active
- 2009-01-23 AU AU2009200257A patent/AU2009200257B2/en not_active Ceased
- 2009-08-05 CR CR10967A patent/CR10967A/es unknown
-
2010
- 2010-08-08 IL IL207458A patent/IL207458A/en not_active IP Right Cessation
- 2010-09-09 JP JP2010201589A patent/JP5309104B2/ja not_active Expired - Lifetime
- 2010-09-27 US US12/891,632 patent/US20110015228A1/en not_active Abandoned
-
2011
- 2011-02-22 JP JP2011035699A patent/JP5925418B2/ja not_active Expired - Lifetime
- 2011-03-08 HK HK11102298A patent/HK1148274A1/xx not_active IP Right Cessation
- 2011-03-30 HK HK11103233A patent/HK1148974A1/xx not_active IP Right Cessation
- 2011-05-26 US US13/117,066 patent/US8431598B2/en not_active Expired - Lifetime
- 2011-09-22 US US13/241,022 patent/US9353080B2/en not_active Expired - Lifetime
- 2011-09-22 US US13/240,976 patent/US9371309B2/en not_active Expired - Lifetime
- 2011-09-22 US US13/240,686 patent/US8822499B2/en not_active Expired - Lifetime
- 2011-10-03 US US13/252,041 patent/US8193219B2/en not_active Expired - Lifetime
- 2011-11-11 CY CY20111101088T patent/CY1112017T1/el unknown
- 2011-11-11 HK HK11112211A patent/HK1157772A1/xx not_active IP Right Cessation
- 2011-11-14 HR HR20110836T patent/HRP20110836T1/hr unknown
-
2012
- 2012-08-27 HK HK12108343A patent/HK1167646A1/xx not_active IP Right Cessation
-
2013
- 2013-04-17 IL IL225792A patent/IL225792A0/en not_active IP Right Cessation
- 2013-04-17 IL IL225791A patent/IL225791A0/en not_active IP Right Cessation
- 2013-05-24 JP JP2013109742A patent/JP2013209407A/ja active Pending
-
2014
- 2014-01-17 JP JP2014006603A patent/JP2014094957A/ja active Pending
-
2015
- 2015-02-23 NO NO20150253A patent/NO337446B1/no unknown
- 2015-03-23 HK HK15102919.7A patent/HK1202531A1/xx unknown
- 2015-05-19 IL IL238911A patent/IL238911A0/en unknown
- 2015-08-14 US US14/827,210 patent/US20160009684A1/en not_active Abandoned
- 2015-11-23 AR ARP150103821A patent/AR102756A2/es unknown
-
2016
- 2016-01-28 NO NO20160131A patent/NO341039B1/no unknown
- 2016-01-28 JP JP2016014010A patent/JP6200977B2/ja not_active Expired - Lifetime
- 2016-06-15 NO NO20161012A patent/NO341035B1/no unknown
- 2016-10-20 US US15/299,164 patent/US20170121303A1/en not_active Abandoned
- 2016-10-20 US US15/299,203 patent/US20170121304A1/en not_active Abandoned
- 2016-10-20 US US15/299,243 patent/US20170121305A1/en not_active Abandoned
-
2017
- 2017-11-03 US US15/803,622 patent/US20180072700A1/en not_active Abandoned
-
2018
- 2018-11-26 US US16/200,514 patent/US10590104B2/en not_active Expired - Lifetime
-
2020
- 2020-03-02 US US16/807,020 patent/US11136306B2/en not_active Expired - Lifetime
-
2021
- 2021-09-02 US US17/465,668 patent/US11655232B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO336898B1 (no) | Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse | |
JP7174735B2 (ja) | (s)-3-(4-((4-(モルホリノメチル)ベンジル)オキシ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 | |
JP2007504248A5 (no) | ||
JP6133383B2 (ja) | 5−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 | |
CA2505964A1 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
KR100747436B1 (ko) | 이소인돌-이미드 화합물 | |
NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister | |
WO2004054974A3 (en) | Piperidine derivatives as ccr5 antagonists | |
JP2018502853A (ja) | 炎症およびがんを処置するための複素環式itk阻害剤 | |
AU2003296993A8 (en) | Cyclopropyl compounds as ccr5 antagonists | |
JP2010522170A (ja) | 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 | |
PT1635824E (pt) | Inibidores de p-38 à base de heterociclos de 5 membros | |
UA94062C2 (en) | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia | |
AU2003297048A8 (en) | Cyclohexyl compounds as ccr5 antagonists | |
TW200920368A (en) | New biaryl derivatives | |
PL370373A1 (en) | Substituted piperidines as modulators of the melanocortin receptor | |
EP3094326A1 (en) | Heteroaryls and uses thereof | |
RU2009122241A (ru) | Твердые формы рацемического илапразола | |
AU2003296992A1 (en) | Pyrrolidine and azetidine compounds as ccr5 antagonists | |
JP2007508336A5 (no) | ||
AU2003300911A1 (en) | Heterocyclic compounds as ccr5 antagonists | |
AU2017356214A1 (en) | Heterocyclic modulators of lipid synthesis | |
TNSN06024A1 (en) | Stable modifications of tegaserod hydrogen maleate | |
AU2010333083A1 (en) | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
HUT58518A (en) | Process for producing pharmaceutical compositions comprising 3-heteroaryl-3-oxopropionitrile derivatives, suitable for treating arthritis and other autoimmune diseases |